Participant flow

Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma · Source last updated 2017-04-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   A single arm, open-label, single institution phase 2 clinical trial is planned. Carfilzomib: Following enrollment patients will be treated with single agent infusional carfilzomib at 56mg/m2. Carfilzomib will be administered intravenously over 30 minutes on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle. Dexamethasone 8 mg PO/IV will be administered prior to all carfilzomib doses during the first cycle.

   id

   FG000

   title

   Carfilzomib

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Protocol Violation

   2. reasons

      1. group Id

         FG000

         num Subjects

         4

      type

      Adverse Event

   3. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Withdrawal by Subject

   4. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Death

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         44

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         35

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         9

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice